BioSenic S.A. (BIOS) - Total Liabilities

Latest as of June 2025: €28.10 Million EUR ≈ $32.85 Million USD

Based on the latest financial reports, BioSenic S.A. (BIOS) has total liabilities worth €28.10 Million EUR (≈ $32.85 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

BioSenic S.A. - Total Liabilities Trend (2011–2024)

This chart illustrates how BioSenic S.A.'s total liabilities have evolved over time, based on quarterly financial data. See BIOS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

BioSenic S.A. Competitors by Total Liabilities

The table below lists competitors of BioSenic S.A. ranked by their total liabilities.

Company Country Total Liabilities
New Energy Metals Corp
V:ENRG
Canada CA$291.23K
Prosper Gold Corp.
V:PGX
Canada CA$200.32K
Fitness Champs Holdings Limited Common Stock
NASDAQ:FCHL
USA $1.90 Million
MEP Infrastructure Developers Limited
NSE:MEP
India Rs35.65 Billion
Lypsa Gems & Jewellery Limited
NSE:LYPSAGEMS
India Rs503.60 Million
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
India Rs7.39 Billion
Oncternal Therapeutics Inc
NASDAQ:ONCT
USA $6.45 Million
Golden Cross Resources Ltd
AU:GCR
Australia AU$10.33 Million

Liability Composition Analysis (2011–2024)

This chart breaks down BioSenic S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOS market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.53 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.19 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 6.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BioSenic S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BioSenic S.A. (2011–2024)

The table below shows the annual total liabilities of BioSenic S.A. from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 €31.55 Million
≈ $36.89 Million
-2.21%
2023-12-31 €32.26 Million
≈ $37.72 Million
+23.15%
2022-12-31 €26.20 Million
≈ $30.63 Million
-1.27%
2021-12-31 €26.54 Million
≈ $31.02 Million
+23.37%
2020-12-31 €21.51 Million
≈ $25.15 Million
+5.73%
2019-12-31 €20.34 Million
≈ $23.79 Million
-4.31%
2018-12-31 €21.26 Million
≈ $24.86 Million
-6.70%
2017-12-31 €22.79 Million
≈ $26.64 Million
-2.25%
2016-12-31 €23.32 Million
≈ $27.26 Million
+4.85%
2015-12-31 €22.24 Million
≈ $26.00 Million
-33.99%
2014-12-31 €33.69 Million
≈ $39.38 Million
+164.25%
2013-12-31 €12.75 Million
≈ $14.90 Million
+8.22%
2012-12-31 €11.78 Million
≈ $13.77 Million
+4.79%
2011-12-31 €11.24 Million
≈ $13.14 Million
--

About BioSenic S.A.

BR:BIOS Belgium Biotechnology
Market Cap
$1.68 Million
€1.44 Million EUR
Market Cap Rank
#30182 Global
#111 in Belgium
Share Price
€0.00
Change (1 day)
+0.00%
52-Week Range
€0.00 - €0.00
All Time High
€20.66
About

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more